Issue

Vol. 64 No. 5: Issue 5

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma

https://doi.org/10.14715/cmb/2018.64.5.12
Min Zhang
Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Zhengzhou University, zhengzhou Henan 450008, China
Qiong Li
Nursing college, Xinxiang Medical University, Xinxiang Henan 453003, China
Lu Zhang
Department of Foreign Languages, Ming De College of Northwestern Polytechnical University, Xi'an 710124, Shaanxi Province, P.R. China
Yunjian Wang
Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Zhengzhou University, zhengzhou Henan 450008, China
Linxia Wang
Foreign Language College, Xi'an Technological University, Shaanxi, 710059, China
Qingjun Li
Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Zhengzhou University, zhengzhou Henan 450008, China
Tao He
Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Zhengzhou University, zhengzhou Henan 450008, China
Baishun Wan
Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Zhengzhou University, zhengzhou Henan 450008, China
Xiaoqian Wang
Department of Hepatobiliary Surgery, The Affiliated Cancer Hospital of Zhengzhou University, zhengzhou Henan 450008, China

Corresponding Author(s) : Qiong Li

liliqiongzhang@163.com

Cellular and Molecular Biology, Vol. 64 No. 5: Issue 5

Abstract

The Ras-association domain family (RASSF) proteins have been involved in many important biological processes. RASSF7 is recently reported to be up-regulated in several types of cancer. However, the function of RASSF7 remain unknown in human cancers. To explore the role of RASSF7 in hepatocellular carcinoma (HCC) cells proliferation and molecular mechanism. RASSF7 expression was examined using public database TCGA, qRT-PCR and Western blot. The correlation between RASSF7 and clinicopathological features was measured. Overexpression and silencing of RASSF7 were performed to measure the impact on HCC cell proliferation, cell cycle and apoptosis. Futhermore, the molecular mechanism of MEK1/2-ERK1/2 signaling pathway regulation by RASSF7 was explored. RASSF7 was significantly up-regulated in HCC tissues and cell lines, and correlated with AFP, poor tumor histology and T stage. Overexpression of RASSF7 promoted HCC cell proliferation, drived G1-S phase cell cycle transition and inhibited apoptosis. Knockdown of RASSF7 suppressed cell growth, induced G1-S phase cell cycle arrest and cell apoptosis. Furthermore, our findings also demonstrated that RASSF7 promoted HCC cell proliferation through activating MEK1/2-ERK1/2 signaling pathway. Taken together, this study provides a novel evidence for clinical significance of RASSF7 as a potential biomarker, and demonstrates that RASSF7- MEK1/2-ERK1/2 signaling pathway might be a novel pathway involved in HCC progression.

Keywords

RASSF7 Hepatocellular carcinoma Proliferation Cell cycle MEK1/2-ERK1/2 pathway.
Zhang, M., Li, Q., Zhang, L., Wang, Y., Wang, L., Li, Q., He, T., Wan, B., & Wang, X. (2018). RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma. Cellular and Molecular Biology, 64(5), 73–79. https://doi.org/10.14715/cmb/2018.64.5.12
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Hong SW, Hur W, Choi JE, Kim JH, Hwang D, Yoon SK. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. Oncotarget 2016; 7:23482-23497.
  2. Watanabe Y, Iwamura A, Shimada YJ, Wakai K, Tamakoshi A, Iso H. Transforming growth factor-β1 as a predictor for the development of hepatocellular carcinoma: a nested case-controlled study. EBioMedicine 2016; 12:68-71.
  3. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66:271-289.
  4. Hong Y, Long J, Li H, Chen S, Liu Q, Zhang B, et al. An analysis of immunoreactive signatures in early stage hepatocellular carcinoma. EBioMedicine 2015; 2:438-446.
  5. Chen C, Song G, Xiang J, Zhang H, Zhao S, Zhan Y. AURKA promotes cancer metastasis by regulating epithelial-mesenchymal transition and cancer stem cell properties in hepatocellular carcinoma. Biochem Biophys Res Commun 2017; 486:514-520.
  6. Yin F, Sharen G, Yuan F, Peng Y, Chen R, Zhou X, et al. TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt/mTOR signaling pathway. Oncogenesis 2017; 6:e347.
  7. He J, Liu Y. Serum TGF-β1: a potential biomarker for early detection of hepatocellular carcinoma. EBioMedicine 2016; 12:4–5.
  8. Xu J, Lin H, Li G, Sun Y, Chen J, Shi L, et al. The miR-367-3p increases sorafenib chemotherapy efficacy to suppress hepatocellular carcinoma metastasis through altering the androgen receptor signals. EBioMedicine 2016; 12:55-67.
  9. Zhao LY, Zhang J, Guo B, Yang J, Han J, Zhao XG, et al. MECP2 promotes cell proliferation by activating ERK1/2 and inhibiting p38 activity in humanhepatocellular carcinoma HEPG2 cells. Cell Mol Biol (Noisy-le-grand). 2013; Suppl 59:OL1876-1881.
  10. Choi J, Lim YS. Genetic-based risk assessment for hepatocellular carcinoma in patients with hepatitis c: where do we stand? EBioMedicine 2017; 15:6–7.
  11. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim. Biophys. Acta Rev. Cancer 2009; 1796:114-128.
  12. Volodko N, Gordon M, Salla M, AbuGhazaleh H, Baksh S. RASSF tumor suppressor gene family: biological functions and regulation. FebsLett 2014; 588:2671-2684.
  13. Lock FE, Underhill-Day N, Dunwell T, Matallanas D, Cooper W, Hesson L, et al. The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-КB signaling pathways. Oncogene 2010; 29:4307-4316.
  14. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009; 8:42.
  15. Schagdarsurengin U, Richter AM, Wohler C, Dammann RH. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 2009; 4:571-576.
  16. Liu W, Wang J, Wang L, Qian C, Qian Y, Xuan H, et al. Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma. Oncogenesis 2016; 5:e237.
  17. Lowe AW, Olsen M, Hao Y, Lee SP, Taek Lee K, Chen X, et al. Gene expression patterns in pancreatic tumors, cells and tissues. PLoS One 2007; 2:e323.
  18. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009; 15:2269-2280.
  19. Tanaka Y, Tateishi K, Nakatsuka T, Kudo Y, Takahashi R, Miyabayashi K, et al. Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression. Oncogenesis 2016; 5:e277.
  20. Huang J, Yang J, Lei Y, Gao H, Wei T, Luo L, et al. An ANCCA/PRO2000-miR-520a-E2F2 regulatory loop as a driving force for the development ofhepatocellular carcinoma. Oncogenesis 2016; 5:e229.
  21. Chauhan R, Churchill ND, Mulrooney-Cousins PM, Michalak TI. Initial sites of hepadnavirus integration into host genome in human hepatocytes and in the woodchuck model of hepatitis B-associated hepatocellular carcinoma. Oncogenesis 2017; 6:e317.
  22. Huang CF, Huang CY, Yeh ML, Wang SC, Chen KY, Ko YM, et al. Genetics variants and serum levels of MHC class I chain-related a in predicting hepatocellular carcinoma development in chronic hepatitis c patients post antiviral treatment. EBioMedicine 2017; 15:81-89.
  23. Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M, et al. Prognostic biomarker identification through integrating the gene signatures of hepatocellular carcinoma properties. EBioMedicine 2017; 19:18-30.
  24. Colas E, Perez C, Cabrera S, Pedrola N, Monge M, Castellvi J, et al. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer 2011; 129:2435-2444.
  25. Djos A, Martinsson T, Kogner P, Carén H. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNAmethylation in neuroblastoma. Mol Cancer 2012; 11:40.
  26. Zhao L, Liu Y, Tong D, Qin Y, Yang J, Xue M, et al. MeCP2 promotes gastric cancer progression through regulating FOXF1/Wnt5a/β-Catenin and MYOD1/Caspase-3 signaling pathways. EBioMedicine 2017; 16:87-100.
  27. Watanabe M, Iizumi Y, Sukeno M, Iizuka-Ohashi M, Sowa Y, Sakai T. The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2. Oncogenesis 2017; 6:e311.
  28. Zhao L, Yao Y, Han J, Yang J, Wang XF, Tong DD, et al. miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2. Dig Dis Sci 2014; 59:1743-1753.
  29. Najas S, Arranz J, Lochhead PA, Ashford AL, Oxley D, Delabar JM, et al. DYRK1A-mediated Cyclin D1 degradation in neural stem cells contributes to the neurogenic cortical defects in down syndrome. EBioMedicine 2015; 2:120-134.
  30. Smith I, Calegari F. Cyclin D1 again caught in the act: DYRK1A links G1 and neurogenesis in down syndrome. EBioMedicine 2015; 2:96-97.
  31. Shimura T, Kobayashi J, Komatsu K, Kunugita N. DNA damage signaling guards against perturbation of cyclin D1 expression triggered by low-dose long-term fractionated radiation. Oncogenesis 2014; 3:e132.
  32. Zhao LY, Tong DD, Xue M, Ma HL, Liu SY, Yang J, et al. MeCP2, a target of miR-638, facilitates gastric cancer cell proliferation through activation of the MEK1/2-ERK1/2 signaling pathway by upregulating GIT1. Oncogenesis 2017; 6:e368.
  33. Zheng L, Qi T, Yang D, Qi M, Li D, Xiang X, et al. microRNA-9 Suppresses the proliferation, invasion and metastasis of gastric cancer cells through targeting Cyclin D1 and Ets1. PLoS One 2013; 8:e55719.
  34. Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, et al. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clin Cancer Res 2012; 18:380-391.
  35. van Reesema LL, Zheleva V, Winston JS, Jansen RJ, O'Connor CF, Isbell AJ, et al. SIAH and EGFR, two ras pathway biomarkers, are highly prognostic in locally advanced and metastatic breast cancer. EBioMedicine 2016; 11:183-198.
  36. Michael JV, Wurtzel JG, Goldfinger LE. Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains. Oncogenesis 2016; 5:e228.
  37. Banda M. Detection of mutant RAS subpopulations in colorectal cancer patients. EBioMedicine 2015; 2:280-281.
  38. RoíŸner F, Gieseler C, Morkel M, Royer HD, Rivera M, Bläker H, et al. Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer. Oncogenesis 2016; 5:e187.
  39. Yoshino T, Muro K, Amaguchi KY, Nishina T, Denda T, Kudo T, et al. Clinical validation of a multiplex kit for RAS mutations in colorectal cancer: results of the RASKET (RAS key testing) prospective, multicenter study. EBioMedicine 2015; 2:317-323.
  40. Wang AG, Song YN, Chen J, Li HL, Dong JY, Cui HP, et al. Activation of RAS/ERK alone is insufficient to inhibit RXRα function and deplete retinoic acid in hepatocytes. Biochem Biophys Res Commun 2014; 452:801-807.
  41. Wang S, Liang Q, Qiao H, Li H, Shen T, Ji F, et al. DISC1 regulates astrogenesis in the embryonic brain via modulation of RAS/MEK/ERK signaling through RASSF7. Development 2016; 143:2732-2740.
  42. Sławińska-Brych A, Zdzisińska B, Dmoszyńska-Graniczka M, Jeleniewicz W, Kurzepa J, Gagoś M, et al. Xanthohumol inhibits the extracellular signal regulated kinase (ERK) signalling pathway and suppresses cell growth of lung adenocarcinoma cells. Toxicology 2016; 357-358:65-73.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 849 Download : 441

Most read articles by the same author(s)